Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.